Business Context and Reporting Period
Company: NanoViricides, Inc. (NNVC)
Filing Type: Form 8-K (Current Report)
Date of Report: July 17, 2026
Event: Entry into a Material Definitive Agreement (At Market Issuance Sales Agreement).
Key Financial Metrics
This filing does not contain financial statements, revenue, profit, cash flow, margin, debt, or liquidity data. The document solely reports the execution of a sales agreement.
Material Changes
On July 17, 2026, the Company entered into an At Market Issuance Sales Agreement with D.Boral Capital LLC. This agreement allows the Company to offer and sell shares of its common stock in an "at the market" offering under Rule 415(a)(4) of the Securities Act of 1933. The offering is conducted pursuant to a prospectus supplement filed under an existing shelf Registration Statement on Form S-3 (File No. 333-296550), which was declared effective on June 15, 2026.
Guidance, Outlook, and Management Commentary
- Sales Mechanism: Sales may be made directly on the NYSE American or other existing trading markets, or through privately negotiated transactions with prior written consent.
- Commission: The Company agreed to pay the Sales Agent a commission equal to 2.0% of the aggregate gross proceeds from each sale.
- Termination: The offering will terminate upon the earlier of the issuance of all placement shares or the termination of the agreement by either party.
- Outlook: No specific financial guidance or future revenue projections were provided in this filing.
Investor Verification Checklist
- Verify the total number of shares authorized for sale under the existing shelf Registration Statement (File No. 333-296550).
- Review the full text of the At Market Issuance Sales Agreement (Exhibit 1.1) for specific termination rights and conditions.
- Monitor future filings for actual sales volumes and proceeds generated under this agreement.
- Assess the potential dilution impact on existing shareholders based on the 2.0% commission structure and future share issuances.